A Phase 1 interventional study of rVV-740CTA in Breast Carcinoma, sponsored by University Hospital, Basel, Switzerland. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-07.
Sponsored by University Hospital, Basel, Switzerland · Phase 1, Interventional, and Treatment
Monocentric open-label phase I/II trial aiming at evaluating, in adjuvant setting, safety (primary outcome), immunological and clinical efficacy (secondary outcomes) of a non replicating recombinant vaccinia virus expressing cancer/testis antigen (CTA) derived epitopes and CD80 and CD40 ligand (CD40L, CD154) costimulatory molecules in patients with CTA expressing tumors.
73 studies on the registry are indexed under Vaccinia; 6 are open to participants now.
Browse Vaccinia studies →University Hospital, Basel, Switzerland is the lead sponsor of 968 studies on the registry; 191 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Biological: rVV-740CTA
non replicating recombinant vaccinia virus expressing 7 Cancer Testis Antigen (CTA) epitopes together with CD80 and CD154(40L)
number of adverse Events
Safety measured by assessment of number of adverse events that have occured
Time frame: 2 years
number of serious adverse Events
Safety measured by assessment of number of serious adverse Events that have occured
Time frame: 2 years
Evolution of Immune reactivity to the CTA
Vaccine epitopes specific CD8+ T-cell responses will be evaluated from peripheral blood samples prior, during and after treatment.
Time frame: 18 months
Disease free survival
number of patients with no relapse of disease at timepoint 2 years
Time frame: 2 years
Overall survival
number of patients still living at timepoint 2 years
Time frame: 2 years
No study locations are listed for this record.
Plan to share: No — publication per reviewed journal
No publications or documents are linked to this record.
This study is withdrawn, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Basel, Switzerland